Immunogenicity of Influenza Vaccine in Long Term Care

Status unconfirmed · Not applicable

Conditions studied: Influenza

In brief

The study is designed to evaluated if adjuvanted vaccine elicits higher T cell and B cell responses than non-adjuvanted standard dose influenza vaccine in nursing home residents.

Key facts

Study ID

NCT02933723

Run by

Insight Therapeutics, LLC

People needed

200

Starts

2016-10-01

Expected to finish

2021-09-01

Last updated by the study team

2021-03-09

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Resident of Medicare Certified Facility (so they have to report Minimum Data Set (MDS) data)
• Residence in a long-term care facility administering a Seqirus influenza vaccine as the standard-of-care.
• Agreed to receive the vaccine that the NH plans to give to them
• >= 65 years old
• Able to obtain consent from subject or legally authorized representative (LAR) and assent from subject
• Able to participate throughout the study period
• Resident for at least 45 days prior to enrollment

You may not qualify if…

• Recent illness (within 30 days) severe enough to require hospitalization or physician-directed outpatient pharmacotherapy
• Receiving chemotherapy for an active cancer

Where it is running

• Case Western Reserve University — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.